Celldex Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Celldex Therapeutics' es Anthony Marucci , nombrado en May 2003, tiene una permanencia de 21.08 años. compensación anual total es $8.36M, compuesta por 8.6% salario y 91.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.043% de las acciones de la empresa, por valor de $996.77K. La antigüedad media del equipo directivo y de la junta directiva es de 8 años y 11.4 años, respectivamente.
Información clave
Anthony Marucci
Chief Executive Officer (CEO)
US$8.4m
Compensación total
| Porcentaje del salario del CEO | 8.6% |
| Permanencia del CEO | 21.1yrs |
| Participación del CEO | 0.04% |
| Permanencia media de la dirección | 8yrs |
| Promedio de permanencia en la Junta Directiva | 11.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns
Jun 07
We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jun 05We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jul 07An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued
Apr 21Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth
Feb 27We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate
Sep 07Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder
Jul 21Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement
Jul 14Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans
May 25Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?
Feb 03Celldex: Pipeline Of Drug Candidates Is Worth A Look
Feb 01Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers
Sep 23We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth
Sep 15Celldex: Powerful Medicines To Yield Further Upsides
Jul 08Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation
May 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$145m |
| Dec 31 2023 | US$8m | US$721k | -US$141m |
| Sep 30 2023 | n/a | n/a | -US$125m |
| Jun 30 2023 | n/a | n/a | -US$113m |
| Mar 31 2023 | n/a | n/a | -US$119m |
| Dec 31 2022 | US$5m | US$693k | -US$112m |
| Sep 30 2022 | n/a | n/a | -US$106m |
| Jun 30 2022 | n/a | n/a | -US$100m |
| Mar 31 2022 | n/a | n/a | -US$77m |
| Dec 31 2021 | US$6m | US$669k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$72m |
| Jun 30 2021 | n/a | n/a | -US$66m |
| Mar 31 2021 | n/a | n/a | -US$64m |
| Dec 31 2020 | US$3m | US$644k | -US$60m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$1m | US$619k | -US$51m |
| Sep 30 2019 | n/a | n/a | -US$50m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$50m |
| Dec 31 2018 | US$1m | US$608k | -US$151m |
| Sep 30 2018 | n/a | n/a | -US$146m |
| Jun 30 2018 | n/a | n/a | -US$165m |
| Mar 31 2018 | n/a | n/a | -US$177m |
| Dec 31 2017 | US$2m | US$598k | -US$93m |
Compensación vs. Mercado: La compensación total de Anthony($USD8.36M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.66M).
Compensación vs. Ingresos: La compensación de Anthony ha aumentado mientras la empresa no es rentable.
CEO
Anthony Marucci (62 yo)
21.1yrs
Permanencia
US$8,361,844
Compensación
Mr. Anthony S. Marucci, M.B.A., has been the Chief Executive Officer and President of Celldex Therapeutics Inc. since September 2008. He co-founded Celldex Therapeutics Inc. in 2004. Mr. Marucci served as...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 21.1yrs | US$8.36m | 0.043% $ 989.6k | |
| Founder | 21.1yrs | US$3.42m | 0.011% $ 254.9k | |
| Senior VP | 6.9yrs | US$2.95m | 0.043% $ 974.8k | |
| Senior Vice President of Regulatory Affairs | 6.7yrs | US$2.94m | 0.020% $ 463.7k | |
| Senior VP & Chief Medical Officer | 5yrs | US$2.97m | 0.026% $ 593.3k | |
| Co-Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Senior Vice President of Corporate Affairs & Administration | 7yrs | sin datos | 0.0028% $ 64.4k | |
| Senior VP & General Counsel | 3.4yrs | US$2.17m | 0.054% $ 1.2m | |
| Chief Business Officer & Senior VP | 12.9yrs | US$1.88m | sin datos | |
| Chief Product Development Officer & Senior VP | 9.9yrs | US$1.18m | 0.014% $ 314.6k | |
| Chief Commercial Officer & Senior VP | 8.9yrs | US$563.17k | 0.032% $ 722.1k |
8.0yrs
Permanencia media
62yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CLDX es experimentado (6.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder | 15.5yrs | US$8.36m | 0.043% $ 989.6k | |
| Co-Founder & Member of Scientific Advisory Board | 2.8yrs | sin datos | sin datos | |
| Independent Director | 27.4yrs | US$371.19k | 0.0042% $ 96.6k | |
| Independent Director | 16.3yrs | US$364.94k | 0.0039% $ 88.9k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 7.3yrs | US$377.44k | 0.019% $ 440.2k | |
| Independent Chair of the Board of Directors | 23.1yrs | US$385.77k | 0.0042% $ 96.6k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 7yrs | US$373.27k | 0.0010% $ 23.1k | |
| Independent Director | 2yrs | US$367.02k | 0% $ 0 |
11.4yrs
Permanencia media
72yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de CLDX son experimentados ( 11.4 años antigüedad media).